Frequency of Metabolic Syndrome in Schizophrenic Patients in a Tertiary Care Hospital, Peshawar, Pakistan
Keywords:
Metabolic syndrome, schizophrenia, Anti-Psychotics, BMI, SmokingAbstract
OBJECTIVES
This study aimed to determine the prevalence of metabolic syndrome in schizophrenic patients in a tertiary care hospital.
METHODOLOGY
This descriptive cross-sectional study was conducted at the Department of Psychiatry, PGMI Lady Reading Hospital Peshawar, Pakistan, from March 2023 to February 2024. A total of 196 schizophrenic patients were studied. After obtaining permission from the hospital's ethical committee and consent from patients included in the study, metabolic syndrome was diagnosed based on the American Association of Clinical Endocrinology criteria (2003). All the data, like age, gender, height, weight, BMI, smoking status, and metabolic syndrome, were recorded in a pre-designed proforma. All the data were analyzed in SPSS version 20. Mean and standard deviation were calculated for numerical variables, and frequencies and percentages for qualitative variables. The Chi-square test for categorical variables was applied with a p-value of < 0.05 as significant. Results were presented in the form of tables and charts.
RESULTS
The mean and standard deviation of age, height, weight, and BMI were 35.72±13.28, 164.80±11.50, 71.87±13.60 and 27.00±6.96, respectively. Out of 196 schizophrenic patients, 59 patients had metabolic syndrome, making up 31.1%, while 69.9% of patients had no metabolic syndrome. Of 196 schizophrenic patients, 106 were female, and 90 were male, making 54.1% and 45.9%, respectively, of all schizophrenic patients. Among 196 patients, 28 were from the BMI group < 18kg/m2, 71 from the BMI group 18-24kg/m2, 51 from the BMI group 25-30kg/m2, and 46 from the BMI group> 30kg/m2 making 14.3%, 36.2%, 26.0% and 23.5% respectively. Metabolic syndrome was statistically significant in age and BMI groups using the chi-square test with a p-value < 0.05 as significant.
CONCLUSION
The metabolic syndrome affects individuals with schizophrenia, particularly among older patients and those with a high BMI. Significant associations were observed with age and BMI, but gender and smoking status did not show significant differences.
Downloads
Metrics
References
Prabhakaran S, Nagarajan P, Varadharajan N, Menon V. Relationship Between Quality of Life and Social Support Among Patients with Schizophrenia and Bipolar Disorder: A Cross-Sectional Study. J Psychosoc Rehabil Ment Health. 2021;8(2):137–45. doi:10.1007/s40737-020-00211-7
Baranne ML, Falissard B. Global burden of mental disorders among children aged 5-14 years. Child Adolesc Psychiatry Ment Health. 2018 Apr 12;12:19.
Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1). doi:10.4088/jcp.ms21078com5
Häfner H. From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness. Psychiatry J. 2019 Apr 16;2019:9804836
Ayub M, Arsalan A, Khan S ud DA, Bajwa S, Hussain F, Umar M, et al. Self-reported health and smoking status, and body mass index: a case-control comparison based on GEN SCRIP (GENetics of SChizophRenia In Pakistan) data. BMJ Open. 2021;11(4):e042331.doi:10.1136/bmjopen-2020-042331
Balõtšev R, Koido K, Vasar V, Janno S, Kriisa K, Mahlapuu R, et al. Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia. European Psychiatry. 2017;39:1–10.doi:10.1016/j.eurpsy.2016.05.010
Gluvic Z, Zaric B, Resanovic I, Obradovic M, Mitrovic A, Radak D, et al. Link between Metabolic Syndrome and Insulin Resistance. Curr Vasc Pharmacol [Internet]. 2016;15(1):30–9.doi:10.2174/1570161114666161007164510
Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome – What is it and how should it be managed? Eur J Prev Cardiol. 2019;26(2_suppl):33–46.doi:10.1177/2047487319886404
Ulaganathan V, Kandiah M, Mohd Shariff Z. A case-control study of the association between metabolic syndrome and colorectal cancer: a comparison of International Diabetes Federation, National Cholesterol Education Program Adults Treatment Panel III, and World Health Organization definitions. J Gastrointest Oncol. 2018 Aug;9(4):650–63
Al-Hamad D, Raman V. Metabolic syndrome in children and adolescents. Transl Pediatr. 2017 Oct;6(4):397–407.
Yoca G, Anıl Yağcıoğlu AE, Eni N, Karahan S, Türkoğlu İ, Akal Yıldız E, et al. A follow-up study of metabolic syndrome in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2019;270(5):611–8.doi:10.1007/s00406-019-01016-x
Sneller MH, de Boer N, Everaars S, Schuurmans M, Guloksuz S, Cahn W, et al. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review. Front Psychiatry. 2021 Mar 29;12:625935.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2019/12/17. 2020 Jan;7(1):64–77
Piras M, Ranjbar S, Laaboub N, Grosu C, Gamma F, Plessen KJ, et al. Evolutions of Metabolic Parameters Following Switches of Psychotropic Drugs: A Longitudinal Cohort Study. Schizophr Bull. 2023 Jan 3;49(1):24–33
Challa F, Getahun T, Sileshi M, Geto Z, Kelkile TS, Gurmessa S, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia. BMC Psychiatry. 2021 Dec 11;21(1):620
Nebhinani N, Tripathi S, Suthar N, Pareek V, Purohit P, Sharma P. Correlates of Metabolic Syndrome in Patients with Schizophrenia: An Exploratory Study. Indian J Clin Biochem. 2020/07/06. 2022 Apr;37(2):232-7
Xing M, Sheng J, Cui M, Su Y, Zhang C, Chen X, et al. Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort. Curr Neuropharmacol. 2022;20(10):1969–77
Sahpolat M, Ari M. Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey. Nord J Psychiatry.2020;75(1):738.doi:10.1080/08039488.2020.1815080
Bowo-Ngandji A, Kenmoe S, Ebogo-Belobo JT, Kenfack-Momo R, Takuissu GR, Kengne-Ndé C, et al. Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis. PLoS One. 2023 Jul 27;18(7):e0289155–e0289155
Rosenthal T, Touyz RM, Oparil S. Migrating Populations and Health: Risk Factors for Cardiovascular Disease and Metabolic Syndrome. Curr Hypertens Rep. 2022/06/15. 2022 Sep;24(9):325–40
Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Canadian Journal of Cardiology.2021;37(5):733–43.doi:10.1016/j.cjca.2021.02.009
Farahbakhsh M, Faramarzi E, Fakhari A, Sadeghi M, Barzegar H, Norouzi S, et al. The PERSIAN Cohort: Prevalence of Psychiatric Disorders Among Employees. Arch Iran Med. 2024 Feb 1;27(2):72–8
Şahin B, İlgün G. Risk factors of deaths related to cardiovascular diseases in World Health Organization (WHO) member countries. Health & Social Care in the Community. 2020;30(1):73–80.doi:10.1111/hsc.13156
Poojari PG, Khan SA, Shenoy S, Acharya LD, Shetty S, Bose S, et al. Identification of risk factors and metabolic monitoring practices in patients on antipsychotic drugs in South India. Asian J Psychiatr.2020;53:102186.doi:10.1016/j.ajp.2020.102186
Saccaro LF, Aimo A, Panichella G, Sentissi O. Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review. Front Psychiatry. 2024 Mar 4;15:1343427.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Fazle Rabbani , Waleed Ahmed
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
